Buys | $0 | 0 | 0 |
Sells | $167,447,842 | 137 | 100 |
Chapman Rowan E | director | 0 | $0 | 3 | $1.16M | $-1.16M |
Marcus Gail Boxer | director | 0 | $0 | 5 | $2.86M | $-2.86M |
Baynes Roy D. | director | 0 | $0 | 1 | $5.44M | $-5.44M |
Fesko John | PRESIDENT, CHIEF BUS. OFFICER | 0 | $0 | 15 | $5.64M | $-5.64M |
RABINOWITZ DANIEL | SEC. AND CHIEF LEGAL OFFICER | 0 | $0 | 14 | $9.74M | $-9.74M |
BOTHA ROELOF | director | 0 | $0 | 1 | $14.79M | $-14.79M |
Moshkevich Solomon | PRESIDENT, CLINICALDIAGNOSTICS | 0 | $0 | 17 | $15.52M | $-15.52M |
Brophy Michael Burkes | CHIEF FINANCIAL OFFICER | 0 | $0 | 33 | $17M | $-17M |
Sheena Jonathan | CO-FOUNDER | 0 | $0 | 21 | $19.21M | $-19.21M |
Rabinowitz Matthew | EXECUTIVE CHAIRMAN | 0 | $0 | 6 | $35.73M | $-35.73M |
Chapman Steven Leonard | CEO AND PRESIDENT | 0 | $0 | 21 | $40.36M | $-40.36M |
Natera, Inc., a diagnostics company, develops and commercializes molecular testing services worldwide. It offers Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus with a blood draw from the mother, as well as twin pregnancies for zygosity; Vistara, a single-gene mutations screening test to identify single-gene disorder; Horizon carrier screening to determine carrier status for various genetic diseases; and Spectrum to identify chromosomal anomalies or inherited genetic conditions during an in vitro …
Over the last 12 months, insiders at Natera, Inc. have bought $0 and sold $167.45M worth of Natera, Inc. stock.
On average, over the past 5 years, insiders at Natera, Inc. have bought $3.98M and sold $94.95M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 219,820 shares for transaction amount of $6.32M was made by Rabinowitz Matthew () on 2022‑05‑12.
2025-03-18 | Sale | Sheena Jonathan | CO-FOUNDER | 5,700 0.0042% | $145.61 | $829,979 | +3.61% | |
2025-03-17 | Sale | Rabinowitz Matthew | EXECUTIVE CHAIRMAN | 1,127 0.0008% | $146.04 | $164,584 | +3.31% | |
2025-03-17 | Sale | Sheena Jonathan | CO-FOUNDER | 181 0.0001% | $146.03 | $26,431 | +3.32% | |
2025-03-17 | Sale | RABINOWITZ DANIEL | SEC. AND CHIEF LEGAL OFFICER | 928 0.0007% | $146.04 | $135,521 | +3.31% | |
2025-03-17 | Sale | Chapman Steven Leonard | CEO AND PRESIDENT | 6,702 0.0049% | $146.03 | $978,678 | +3.32% | |
2025-03-17 | Sale | Fesko John | PRESIDENT, CHIEF BUS. OFFICER | 795 0.0006% | $146.04 | $116,099 | +3.31% | |
2025-03-17 | Sale | Moshkevich Solomon | PRESIDENT, CLINICALDIAGNOSTICS | 1,026 0.0007% | $146.04 | $149,836 | +3.31% | |
2025-03-17 | Sale | Brophy Michael Burkes | CHIEF FINANCIAL OFFICER | 792 0.0006% | $146.04 | $115,661 | +3.31% | |
2025-03-14 | Sale | Rabinowitz Matthew | EXECUTIVE CHAIRMAN | 50,000 0.0369% | $147.71 | $7.39M | +0.69% | |
2025-03-12 | Sale | Marcus Gail Boxer | director | 1,014 0.0008% | $145.86 | $147,907 | +2.57% | |
2025-03-12 | Sale | Marcus Gail Boxer | director | 4,000 0.003% | $147.69 | $590,773 | +2.57% | |
2025-03-05 | Sale | Chapman Steven Leonard | CEO AND PRESIDENT | 87,272 0.0626% | $143.40 | $12.52M | -2.98% | |
2025-03-05 | Sale | Moshkevich Solomon | PRESIDENT, CLINICALDIAGNOSTICS | 6,000 0.0043% | $143.29 | $859,734 | -2.98% | |
2025-02-26 | Sale | Sheena Jonathan | CO-FOUNDER | 5,600 0.0042% | $160.47 | $898,609 | -10.45% | |
2025-02-06 | Sale | Fesko John | PRESIDENT, CHIEF BUS. OFFICER | 663 0.0005% | $177.77 | $117,862 | -11.05% | |
2025-02-06 | Sale | Moshkevich Solomon | PRESIDENT, CLINICALDIAGNOSTICS | 1,632 0.0012% | $177.77 | $290,121 | -11.05% | |
2025-02-03 | Sale | Brophy Michael Burkes | CHIEF FINANCIAL OFFICER | 43,502 0.0329% | $176.88 | $7.69M | -11.30% | |
2025-01-31 | Sale | Sheena Jonathan | CO-FOUNDER | 163 0.0001% | $176.60 | $28,786 | -10.98% | |
2025-01-31 | Sale | Brophy Michael Burkes | CHIEF FINANCIAL OFFICER | 2,286 0.0017% | $175.98 | $402,288 | -10.98% | |
2025-01-31 | Sale | Brophy Michael Burkes | CHIEF FINANCIAL OFFICER | 1,886 0.0014% | $176.60 | $333,068 | -10.98% |
Rabinowitz Matthew | EXECUTIVE CHAIRMAN | 2364288 1.7489% | $356.7M | 1 | 74 | +52.44% |
BOTHA ROELOF | director | 1224787 0.906% | $184.78M | 2 | 2 | +4.55% |
HEALY JAMES | director | 0 0% | $0 | 3 | 2 | <0.0001% |
Steuart John | director | 0 0% | $0 | 1 | 1 | <0.0001% |
$53,318,456 | 175 | 15.57% | $439.27M | |
$38,597,637 | 114 | 658.88% | $2.09M | |
$1,590,764 | 16 | 3.90% | $51.8M | |
Natera, Inc. (NTRA) | $26,663,659 | 7 | -12.13% | $20.4B |
$151,252 | 6 | -58.10% | $23.96M |
Increased Positions | 323 | +56.77% | 17M | +14% |
Decreased Positions | 256 | -44.99% | 13M | -10.88% |
New Positions | 137 | New | 3M | New |
Sold Out Positions | 43 | Sold Out | 579,247 | Sold Out |
Total Postitions | 636 | +11.78% | 127M | +3.12% |
Vanguard Group Inc | $1.83M | 9.12% | 12.32M | +879,463 | +7.69% | 2024-12-31 |
Blackrock, Inc. | $1.36M | 6.8% | 9.18M | +947,457 | +11.51% | 2024-12-31 |
Price T Rowe Associates Inc /Md/ | $999,363.00 | 4.99% | 6.74M | +4M | +134.88% | 2024-12-31 |
Jpmorgan Chase & Co | $993,285.00 | 4.96% | 6.7M | +2M | +44.68% | 2024-12-31 |
Farallon Capital Management Llc | $656,853.00 | 3.28% | 4.43M | -125,700 | -2.76% | 2024-12-31 |
Duquesne Family Office Llc | $528,679.00 | 2.64% | 3.57M | 0 | 0% | 2024-12-31 |
Wellington Management Group Llp | $480,239.00 | 2.4% | 3.24M | +439,778 | +15.71% | 2024-12-31 |
Fred Alger Management, Llc | $447,301.00 | 2.24% | 3.02M | -994,184 | -24.78% | 2024-12-31 |
State Street Corp | $443,322.00 | 2.22% | 2.99M | -503,369 | -14.4% | 2024-12-31 |
Rtw Investments, Lp | $384,382.00 | 1.92% | 2.59M | 0 | 0% | 2024-12-31 |